DEEP TRACK CAPITAL LP
Q4 2024 Form 13-F
GREENWICH, CONNECTICUT
CIK 0001856083
· CRD 312459
· SEC-registered investment adviser
$2.7B Reported Value Total
DEEP TRACK CAPITAL, LP reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $5,194,322,737, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $8.4B gross asset value
Hedge Fund: $8.4B
Source: Form ADV filed 2026-03-31
Reported value
$2.7B
Quarter over quarter
-5.7%
Holdings
61
Top-10 concentration
52.0%
Key People
Form ADV owners & control persons
David Eric Kroin
MANAGING MEMBER
Nir Salman Messafi
CHIEF OPERATING AND FINANCIAL OFFICER / CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2024 13F record
Q4 2024 13F filing summary
| Period of report | December 31, 2024 |
|---|---|
| Filed | February 14, 2025 |
| Form | 13F-HR |
| Reported value | $2.7B |
| Positions | 61 |
| Change in reported value | -15.0% |
| New positions | 14 |
| Exited positions | 22 |
| Position turnover | 43.4% |
| Top-10 concentration | 52.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
66 | $6.9B |
|
Q1 2026 13F
Filed May 15, 2026
|
62 | $6.1B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
53 | $5.6B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
56 | $3.6B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
65 | $3.1B |
|
Q1 2025 13F
Filed May 15, 2025
|
69 | $3.1B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
61 | $2.7B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
69 | $3.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
67 | $3.4B |
|
Q1 2024 13F
Filed May 15, 2024
|
65 | $3.5B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
57 | $3.0B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
62 | $2.6B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
53 | $2.2B |
|
Q1 2023 13F
Filed May 15, 2023
|
54 | $2.4B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
57 | $2.4B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
60 | $2.2B |
|
Q2 2022 13F
Filed Aug 12, 2022
|
49 | $1.5B |
|
Q1 2022 13F
Filed May 16, 2022
|
49 | $1.6B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
49 | $1.4B |
Top 20 holdings · Q4 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | DVAX DYNAVAX TECHNOLOGIES CORP | $227.2M | 8.47% |
| 2 | GH GUARDANT HEALTH INC | $196.1M | 7.31% |
| 3 | ITCI INTRA-CELLULAR THERAPIES INC | $167.0M | 6.23% |
| 4 | IMVT IMMUNOVANT INC | $148.6M | 5.54% |
| 5 | APLS APELLIS PHARMACEUTICALS INC | $136.4M | 5.09% |
| 6 | SWTX SPRINGWORKS THERAPEUTICS INC | $125.0M | 4.66% |
| 7 | CYTK CYTOKINETICS INC | $117.6M | 4.39% |
| 8 | OCUL OCULAR THERAPEUTIX INC | $109.6M | 4.09% |
| 9 | VRDN VIRIDIAN THERAPEUTICS INC | $86.7M | 3.23% |
| 10 | PLRX PLIANT THERAPEUTICS INC | $78.7M | 2.93% |
| 11 | GPCR STRUCTURE THERAPEUTICS INC | $75.9M | 2.83% |
| 12 | IONS IONIS PHARMACEUTICALS INC | $67.6M | 2.52% |
| 13 | NRIX NURIX THERAPEUTICS INC | $56.5M | 2.11% |
| 14 | MBX MBX BIOSCIENCES INC | $55.6M | 2.08% |
| 15 | ETNB 89BIO INC | $50.7M | 1.89% |
| 16 | HRMY HARMONY BIOSCIENCES HLDGS IN | $49.9M | 1.86% |
| 17 | DYN DYNE THERAPEUTICS INC | $47.1M | 1.76% |
| 18 | SEPN SEPTERNA INC | $43.8M | 1.63% |
| 19 | NMRA NEUMORA THERAPEUTICS INC. | $42.4M | 1.58% |
| 20 | GMAB GENMAB A/S | $41.7M | 1.56% |
Values as reported on the Q4 2024 Form 13F. Every position is in the holdings table below.